Bengaluru: Equillium, Inc., a clinical-stage biotechnology company and Biocon Limited, an innovation-led global ...

Equillium and Biocon announce positive data from phase 2 study of itolizumab to treat moderate to severe ulcerative colitis: Our Bureau, Bengaluru Friday, February 7, 2025, 10:30 ...

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a ...

People living with inflammatory bowel disease (IBD) have new hope, with clinical trials beginning for a breakthrough treatment for one of the most ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...

The findings from the PROSPERO study reveal that multiple hospitalizations, long-term disease duration, prior surgeries, and factors like corticosteroid use and total parenteral nutrition ...

Researchers from The Institute of Cancer Research in London have developed a new test that can predict colorectal cancer risk ...

A ground-breaking method for predicting bowel cancer among those at higher risk has achieved over 90% accuracy, according to ...